About Aria CV
Aria CV is a Healthcare company based in Saint Paul (United States) founded in 2010 by Karl Vollmers. Device for pulmonary hypertension. Aria CV has raised $44.98 million across 6 funding rounds from investors including Longview Partners, Xeraya Capital and Frontcourt. The company has 17 employees. Its chief executive, as recorded, is Dan Gladney. Aria CV offers products and services including Aria CV Device. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Medical Devices and Therapeutic Devices. Its legal entity is ARIA CV Inc. Its competitors include Adient Medical, Bellerophon Therapeutics and Crux Biomedical; 2 of its 3 listed competitors have raised funding.
Company details
Aria CV was founded in 2010 in Saint Paul, United States, by Drs. John Scandurra and Karl Vollmers, with an exclusive license to patents from the University of Minnesota. A medical device is being developed in the cardiovascular sector to reduce right heart workload for pulmonary hypertension patients. Operations focus on device innovation, led by Co-Founder Karl Vollmers as VP of RD and CEO Dan Gladney.
- Headquarters Saint Paul, United States
- Employees 17
- Founders Karl Vollmers
- SectorsHealthcare
- Website ariacv.com
- Social LinkedIn
- Legal Name Aria Cv Inc
- Total Equity Funding$44.98M (USD)
in 6 rounds
- Latest Funding Round$1.38M (USD), Seed
Aug 2025
- InvestorsLongview Partners
& 7 more
- Employee Count17
Products & Services of Aria CV
Aria CV offers a comprehensive portfolio of products and services, including Aria CV Device.
Implantable system for treating pulmonary hypertension via heart-driven mechanics.
Funding Insights of Aria CV
Aria CV has successfully raised a total of $44.98M across 6 strategic funding rounds. The most recent funding activity was a Seed round of $1.38 million completed in August 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $44.98M
- Total Rounds 6
- Last Round Seed — $1.38M
- First Round $7.8M
(Jul 2015)
- Investors Count 8
All 6 funding rounds of Aria CV with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2025 | $1.38M | Seed | – | – | – |
| Sep 2024 | $2.22M | Series B | – | – | – |
| Feb 2020 | $31M | Series B | – | Xeraya Capital | |
| Jan 2020 | $666,600 | Series A | – | – | – |
| Mar 2018 | $1.92M | Series A | – | – | – |
| Jul 2015 | $7.8M | Series A | – | CHV |
8 investors in total: 8 institutional.
Investors in Aria CV
Aria CV has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Longview Partners, Xeraya Capital and Frontcourt.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity investment firm | xeraya.com | Kuala Lumpur, Malaysia | ||
| chv.vc | ||||
Healthtech startups are funded by BioStar Capital's venture capital efforts. | biostarcapital.com | Charlevoix, United States | ||
Seed-stage life sciences investments are made in the US. | broadviewventures.org | Boston, United States | ||
Investment management services are provided by Longview Partners in London. | 2001 | longview-partners.com | London, United Kingdom | |
| frontcourtgroup.com | ||||
Offers fiduciary financial planning, portfolio management, and consulting for clients. | 2022 | cedarpointcap.com | Cedar Rapids, United States | |
| cedarpointcapitalgroup.com |
Investor details for Aria CV
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Aria CV
7 people are tracked at Aria CV (5 in leadership, 2 in team); the tracked headcount is 17.
| Name | Role | Group |
|---|---|---|
Karl Vollmers | Co-Founder & VP of R&D | Leadership |
Dan Gladney | Chief Executive Officer | Leadership |
Peter Delange | Chief Technology Officer | Leadership |
Joshua Woolley | Vice President Clinical And Regulatory Affairs | Leadership |
Gary Graham | Vice President Operations | Leadership |
Clarence Coryell | Spencer H. Kubo, MD | Team |
Amy Moe | Office Manager | Team |
Complete people profiles for Aria CV
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Aria CV
3 dated milestones of Aria CV across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Aria CV is founded.
- Funding First funding round of $7.8M.
- Funding Latest funding round, Seed, of $1.4M.
Competitors of Aria CV
Aria CV has 3 listed competitors in our database, 2 of them funded. They include Adient Medical, Bellerophon Therapeutics and Crux Biomedical.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| adientmedical.com | 2012 | Pearland, United States | $19.43M | 6,421 | Bioabsorbable medical devices are developed for pulmonary embolism prevention. | |
| bellerophon.com | 2014 | Hampton, United States | 18 | Drug-device therapies for pulmonary hypertension are developed. | ||
| cruxbiomedical.com | 2004 | Menlo Park, United States | $8M | Retrievable vena cava filters are developed to prevent pulmonary emboli. |
Detailed competitors of Aria CV
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Aria CV
The website of Aria CV (ariacv.com) receives about 1.4K visits a month.
- Monthly visits1.4K
▲ 22.4% vs previous month
Top companies in Cardiac and Vascular Disorders
3 companies that operate in the same segment as Aria CV (Cardiac and Vascular Disorders) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Gene-editing therapies for coronary artery disease are developed. | 2018 | Cambridge, Massachusetts, United States | USD 215.5 M | 255 | ||
Cardiac monitoring devices and applications are provided for heart health. | 2010 | Mountain View, California, United States | USD 114.38 M | USD 6.18 M | 67 | |
Therapies for lowering low-density lipoprotein cholesterol levels are developed. | 1998 | Ann Arbor, Michigan, United States | USD 129.7 M | USD 332.31 M | 304 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Aria Cv
Complete news archive for Aria CV
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aria CV
Aria CV was founded in 2010 and raised its 1st funding round 5 years after it was founded.
Aria CV is headquartered in Saint Paul, United States. It is registered at Saint Paul, Minnesota, United States.
Dan Gladney is the CEO of Aria CV, as recorded in our data.
Aria CV is a funded company, having raised a total of $44.98M across 6 funding rounds to date. The company's 1st funding round was a Series A of $7.8M, raised on Jul 2015.
Aria CV has 17 employees.
Aria CV was founded in 2010 in Saint Paul, United States, by Drs. John Scandurra and Karl Vollmers, with an exclusive license to patents from the University of Minnesota. A medical device is being developed in the cardiovascular sector to reduce right heart workload for pulmonary hypertension patients. Operations focus on device innovation, led by Co-Founder Karl Vollmers as VP of RD and CEO Dan Gladney.
Aria CV's top competitors include Adient Medical, Bellerophon Therapeutics and Crux Biomedical.
Aria CV offers Aria CV Device.
Aria CV has 8 investors. Key investors include Longview Partners, Xeraya Capital, Frontcourt, CHV, and BioStar Capital.
Aria CV operates through Aria Cv Inc.